Company profile
IRIDEX Corporation
NASDAQ: IRIX · Healthcare · Medical - Devices
#429 of 1,422 Healthcare companies by revenue53rd-percentile growth
EA Score
55CFH 51DQ 57GM 54SS 67
v0.1 · 65/100 weight · provisional
↑ disclosure history, listing tenure · ↓ Piotroski F, filing timeliness
Methodology →Revenue TTM
$52.6M
Rev growth YoY (TTM)
+7.7%
Net income (FY)
-$4.4M
Employees
93
as of 2026-08-21
Market cap
$13.2M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$52.7M$52.7M2026
Net income-$4.4M-$4.4M2026
Operating income-$2.6M-$2.6M2026
Total assets$29.2M$29.2M2026
Liabilities$24.2M$24.2M2026
Equity$4.9M$4.9M2026
Revenue trend
FY2018 – FY2026 · USD
FY18
FY19
FY21
FY21
FY22
FY23
FY24
FY26
Revenue by segment
Filed disclosures · FY2025
By product
Retina57%
Cyclo G Six26%
Product and Service, Other16%
By geography
UNITED STATES44%
Europe, Middle East and Africa27%
Asia Pacific25%
Americas Excluding U S4%
The read
What is IRIDEX Corporation’s revenue?
IRIDEX Corporation booked $52.7M in FY2026 revenue, growing 8.2% year over year — about the middle of the pack among Healthcare companies we track, at a -8.4% net margin.
Peers · Healthcare
Regional Health Properties, Inc.67BApyx Medical Corporation64CProtalix BioTherapeutics, Inc.66B1CM Inc.70BONE Bio Corp.——Vext Science, Inc.64CNeighbors
Santa Clara →Key facts
CEOPatrick Mercer
SectorHealthcare
IndustryMedical - Devices
HeadquartersMountain View, CA
ExchangeNASDAQ: IRIX
Employees93
IPO date1996-02-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.